2. Academic Validation
  3. M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition

M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition

  • Neuropsychopharmacology. 2018 Jul;43(8):1763-1771. doi: 10.1038/s41386-018-0033-9.
Sean P Moran 1 2 3,  Jonathan W Dickerson 2 3,  Hyekyung P Cho 2 3,  Zixiu Xiang 2 3,  James Maksymetz 2 3,  Daniel H Remke 2 3,  Xiaohui Lv 2 3,  Catherine A Doyle 2 3,  Deepa H Rajan 2 3,  Colleen M Niswender 2 4 5,  Darren W Engers 2 3,  Craig W Lindsley 2 4,  Jerri M Rook 2 3,  P Jeffrey Conn 6 7 8 9
Affiliations

Affiliations

  • 1 Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, 37232, USA.
  • 2 Department of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA.
  • 3 Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, 37232, USA.
  • 4 Department of Chemistry, Vanderbilt University, Nashville, TN, 37232, USA.
  • 5 Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN, 37240, USA.
  • 6 Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, 37232, USA. jeffrey.conn@vanderbilt.edu.
  • 7 Department of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA. jeffrey.conn@vanderbilt.edu.
  • 8 Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, 37232, USA. jeffrey.conn@vanderbilt.edu.
  • 9 Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN, 37240, USA. jeffrey.conn@vanderbilt.edu.
PMID: 29581537 DOI: 10.1038/s41386-018-0033-9
Abstract

Highly selective positive allosteric modulators (PAMs) of the M1 subtype of Muscarinic Acetylcholine Receptor have emerged as an exciting new approach for improving cognitive function in patients suffering from Alzheimer's disease and schizophrenia. However, excessive activation of M1 is known to induce seizure activity and have actions in the prefrontal cortex (PFC) that could impair cognitive function. We now report a series of pharmacological, electrophysiological, and behavioral studies in which we find that recently reported M1 PAMs, PF-06764427 and MK-7622, have robust agonist activity in cell lines and agonist effects in the mouse PFC, and have the potential to overactivate the M1 receptor and disrupt PFC function. In contrast, structurally distinct M1 PAMs (VU0453595 and VU0550164) are devoid of agonist activity in cell lines and maintain activity dependence of M1 activation in the PFC. Consistent with the previously reported effect of PF-06764427, the ago-PAM MK-7622 induces severe behavioral convulsions in mice. In contrast, VU0453595 does not induce behavioral convulsions at doses well above those required for maximal efficacy in enhancing cognitive function. Furthermore, in contrast to the robust efficacy of VU0453595, the ago-PAM MK-7622 failed to improve novel object recognition, a rodent assay of cognitive function. These findings suggest that in vivo cognition-enhancing efficacy of M1 PAMs can be observed with PAMs lacking intrinsic agonist activity and that intrinsic agonist activity of M1 PAMs may contribute to adverse effects and reduced efficacy in improving cognitive function.

Figures
Products